title: EZH2: an epigenetic gatekeeper promoting lymphomagenesis.
abstract: In this issue of Cancer Cell, Béguelin and colleagues highlight EZH2 as an essential regulator for B cell activation and report an addiction of germinal center-derived neoplasms to EZH2 activity. This reversible process is specifically targetable and hence presents high translational value for lymphoma therapy.
authors.affiliation: Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Catalonia, Spain.
authors.forename: Holger
authors.initials: H
authors.lastname: Heyn
authors.forename: Manel
authors.initials: M
authors.lastname: Esteller
mesh_terms: D000818:Animals; D001402:B-Lymphocytes / Q000378:metabolism*; D002471:Cell Transformation, Neoplastic / Q000235:genetics*; D000071221:Enhancer of Zeste Homolog 2 Protein; D018858:Germinal Center / Q000378:metabolism*; D009154:Mutation; D063151:Polycomb Repressive Complex 2 / Q000502:physiology*
chemical_list: D000071221:Enhancer of Zeste Homolog 2 Protein; C498410:Ezh2 protein, mouse; D063151:Polycomb Repressive Complex 2